Arcturus fails to nominate FY17 statement auditor

Arcturus Therapeutics Ltd. (NASDAQ:ARCT) said its shareholders did not ratify the appointment of Ernst & Young as independent auditors of the RNA therapeutics company’s 2017 financial statements, which could delay or altogether prevent filing of its 2017 annual report and potentially lead to its delisting from NASDAQ.

The appointment of new independent auditors was ratified on Feb. 5 by unanimous approval of the board, including former President and CEO Joseph Payne. According to Arcturus, Payne was fired on Feb. 1 but voted as part of his fiduciary responsibility as a member of the board. Arcturus said that Payne then voted his shares against the proposal on Feb. 26, which led to its rejection...